Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry
- 14 May 2010
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 91 (5) , 855-864
Abstract
We retrospectively analyzed the results of 707 adult patients who underwent myeloablative peripheral blood stem cell transplantation (PBSCT) (n = 365) and myeloablative bone marrow transplantation (BMT) (n = 342) for leukemia from HLA-identical sibling donors between 2000 and 2005 using the propensity score method. The results were obtained from the Japan Society for Hematopoietic Cell Transplantation registry. Multivariate Cox analysis showed that PBSCT was associated with lower overall survival (OS) in standard-risk patients [adjusted hazard ratio (aHR) = 1.83; 95% confidence interval (CI) 1.04–3.23; P = 0.036], but not in high-risk patients (aHR = 1.11; 95% CI 0.76–1.61; P = 0.599). Hematopoietic recovery was significantly faster after PBSCT. The risk of acquiring grade III–IV acute graft-versus-host disease (GVHD) (aHR = 2.23; P = 0.040) and extensive chronic GVHD (aHR = 1.93; P = 0.001) were significantly higher after PBSCT. PBSCT was associated with higher non-relapse mortality in standard-risk patients (aHR = 2.30; 95% CI 1.08–4.88; P = 0.030), but not in high-risk patients (aHR = 1.29; 95% CI 0.65–2.54; P = 0.468). Relapse after transplantation did not differ between PBSCT and BMT either in standard-risk group or in high-risk group (aHR = 1.17; 95% CI 0.55–2.52; P = 0.684 and aHR = 0.81; 95% CI 0.52–1.28; P = 0.370, respectively). In this retrospective analysis, OS was significantly lower after PBSCT in standard-risk patients, but not in high-risk patients. PBSCT was associated with significant risks of grade III–IV acute GVHD and extensive chronic GVHD.Keywords
This publication has 39 references indexed in Scilit:
- Peripheral blood progenitor cell or bone marrow transplantation: controversy remainsCurrent Opinion in Oncology, 2008
- Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow TransplantationBlood, 2006
- A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignanciesBlood, 2002
- Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemiaBlood, 2002
- Blood or marrow?The Lancet, 2000
- Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation, 1999
- A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignanciesBone Marrow Transplantation, 1998
- Antileukemic Effect of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1981
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958